First Manhattan’s Fulcrum Therapeutics FULC Stock Holding History

First Manhattan’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-116,622	Closed	-$2.76M	–	1591
2022 Q1	$2.76M	Buy	+116,622	New	+$1.65M	0.01%	323

Other funds holding FULC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan's FULC Position: Q2 2022 in Review

First Manhattan sold out of Fulcrum Therapeutics (FULC) in Q2 2022, closing a stake of 116,622 shares — an estimated $2.76M sold.

First Manhattan first reported a position in FULC in Q1 2022 and held it in 1 quarter. The position peaked at $2.76M in Q1 2022. 101 funds tracked by Wall St. Rank hold FULC as of Q2 2022.

First Manhattan reported no remaining Fulcrum Therapeutics position as of Q2 2022 after selling out during the quarter.
First Manhattan sold 116,622 Fulcrum Therapeutics shares in Q2 2022, an estimated $2.76M.
First Manhattan first reported a position in Fulcrum Therapeutics in Q1 2022 and held it in 1 quarter.
First Manhattan's Fulcrum Therapeutics position peaked at $2.76M in Q1 2022.
101 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2022.

Based on First Manhattan's 13F filing for Q2 2022, filed 15 Aug 2022.